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Abstract
Background: A subset of patients with serology suggesting celiac disease have an initially negative biopsy but
subsequently develop histopathologic celiac disease. Here we characterize patients with potential celiac disease
who progress to celiac disease.
Methods: We performed a retrospective analysis of children (0–18 years of age) with biopsy-confirmed celiac
disease seen at St. Louis Children’s Hospital between 2013 and 2018.
Results: Three hundred sixteen of 327 (96%) children with biopsy-confirmed celiac disease were diagnosed on
initial biopsy. The 11 children with potential celiac disease who progressed to celiac disease had lower anti-tissue
transglutaminase (anti-TTG IgA) concentrations (2.4 (1.6–5) X upper limit of normal (ULN) vs. 6.41 (3.4–10.5) X ULN)
at time of first biopsy. Their median anti-TTG IgA concentrations rose from 2.4 (1.6–5) X ULN to 3.6 (3.1–9.2) X ULN
between biopsies.
Conclusions: Four percent of biopsy confirmed celiac patients initially had a negative biopsy, but later developed
histopathologic celiac disease. This is likely an underestimate as no surveillance algorithm was in place. We recommend
repeat assessment in children whose serology suggests celiac disease despite normal small bowel biopsy.
Keywords: Celiac disease, Potential celiac disease, Pediatrics, Biopsy

Introduction
Celiac disease is an autoimmune enteropathy triggered
by gluten and its related proteins found in wheat, rye,
and barley. Celiac disease causes inflammation and small
intestinal damage of varying severity, and can have longterm adverse effects on growth and development [1].
The diagnosis of celiac disease is typically made with a
combination of serological testing, including tissue transglutaminase (TTG IgA), anti-endomysial (EMA IgA), and
deamidated gliadin (DGP) antibodies, as well as upper
endoscopy with biopsy findings of villous blunting, villous
atrophy, or crypt hyperplasia [1, 2]. A subset of patients in
* Correspondence: loriholtz@wustl.edu
Department of Pediatrics, Washington University School of Medicine, 660 S.
Euclid, Campus, Box 8208, St. Louis, MO 63110, USA

the population have positive celiac serology, but have normal duodenal villous architecture on endoscopy [3, 4].
This situation has been termed potential celiac disease [3–
5]. Of particular interest, are the patients with positive serology and an initially normal biopsy, who develop villous
atrophy on a subsequent biopsy.
Previous studies have suggested that the amount of
intraepithelial lymphocytosis (IEL) on initial biopsy [6,
7], the presence of EMA IgA [8, 9], or the presence of
certain HLA-DR and DQ genotyping [10–12] can serve
as good markers for progression to celiac disease. Our
study aims to additionally characterize patients with potential celiac disease who progress to celiac disease by
variables such as age, sex, race, comorbidities, and laboratory values. Using these predictive characteristics,
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we hope for more accurate identification of patients with
initially elevated celiac serology who will then go on to
develop disease, and thus create a new framework for
the diagnosis and management of the disease.

Methods
Patients and data collection

This study was approved by the Washington University
Human Research Protection Office. We conducted a
retrospective chart review of children (< 18 years old)
treated by the Division of Pediatric Gastroenterology,
Hepatology, and Nutrition at St. Louis Children’s Hospital (SLCH) between November 2013 and May 2018. St.
Louis Children’s Hospital is a tertiary, free-standing 402
bed children’s hospital serving a six state region. Our
study’s inclusion criteria were relevant ICD-9 and 10
codes (579.0, K90.0, R76.0, R76.8, R76.9, R89.4, 795.79),
anti-TTG IgA concentration available at time of evaluation, and at least one upper endoscopy with four biopsies taken from the second portion of the duodenum
and two from the bulb [1]. At SLCH modified Marsh
scores and CD3 staining were not universally reported
by the pathologists. A biopsy was defined as positive for
celiac disease if it demonstrated villous blunting or atrophy or crypt hyperplasia. It was considered negative if
the villi appeared normal or there was intraepithelial
lymphocytosis characterized as “mild” in the pathology
report.
All information was extracted from SLCH’s electronic
medical record. Because laboratories have differing normal ranges for circulating anti-TTG IgA concentrations
based on assay kit, values were described in relation to
the upper limit of normal (times the upper limit of normal, X ULN) of the test as used in previous studies [13].
The World Health Organization anthropometric calculator was used to obtain height-for-age Z-score (HAZ)
and weight-for-age Z-score (WAZ), as well as percentiles.
Statistical methods

Data collected in this study were analyzed using Prism
(v8.4.1) statistical software. The Mann-Whitney test was
used to determine whether there was a statistical difference between continuous variables such as TTG concentrations. The Fisher Exact test was used to calculate p
values for presence or absence of type I diabetes,
hypothyroidism, and trisomy 21 in the celiac disease and
potential celiac disease groups. All p-values were two
tailed. All data are presented as median (interquartile
range) or number (percentile), as appropriate.

Results
We identified 327 patients with biopsy-confirmed celiac
disease at St. Louis Children’s Hospital during the study
interval. Children with initially potential celiac disease
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who progressed to celiac disease were referred for celiac
evaluation predominantly for other autoimmune conditions
(i.e. type I diabetes mellitus, hypothyroidism), trisomy 21,
and symptoms consistent with celiac disease including abdominal pain, constipation, diarrhea, and poor growth.
Children with celiac disease confirmed on the initial biopsy
were additionally referred because of family history of celiac
disease, and/or other gastrointestinal illnesses (i.e. eosinophilic esophagitis, inflammatory bowel disease). Serological
testing in the combined celiac disease and potential celiac
disease who progressed to celiac disease groups consisted
of anti-TTG IgA (100%), anti-EMA IgA (18%), and antiDGP IgG (8%). These laboratory values were obtained at either St. Louis Children’s Hospital (78%), or other laboratories in our region (22%).
We also identified 29 additional patients who had initially elevated anti-TTG IgA concentrations with a normal first biopsy, but who underwent a second biopsy
that was negative and therefore were not diagnosed with
celiac disease (n = 6, 2%), had anti-TTG IgA concentration that normalized on repeat testing and therefore did
not undergo repeat endoscopy (n = 16, 4%), or were lost
to follow up (n = 7, 2%) (Fig. 1).
Of the 327 patients with biopsy-confirmed celiac disease, 316 (96%) had a positive initial biopsy. Eleven (4%)
had a negative initial biopsy. Eight of these 11 (73%) had
evidence of mild IEL on biopsy and 3 had no histological
abnormalities. These 11 patients remained on a glutencontaining diet while their celiac serology was serially
monitored, and, on repeat biopsy, had histologic features
of celiac disease.
Of the 316 patients with a positive initial biopsy, 220
(70%) patients were female (Table 1). The median antiTTG IgA concentration for patients with celiac disease
confirmed on initial biopsy was 6.41 (3.4–10.5) X ULN
(Fig. 2). Notably, only 104 (33%) of the patients who had
abnormal anti-TTG IgA concentrations and a positive
biopsy had anti-TTG IgA concentrations > 10 X ULN.
Furthermore, 66 (21%) patients even had an anti-TTG
IgA concentration < 3 X ULN with a positive biopsy.
Of the 11 children with potential celiac disease who
then progressed to celiac disease, 8 (73%) were female
(Table 1). Each of these 11 patients had abnormal antiTTG IgA concentrations at the time of initial intestinal
biopsy, and 10 had persistently elevated anti-TTG IgA at
the time of the second biopsy. All reported remaining
on a gluten-containing diet. The median interval between the first and second biopsies was 14 (10–30)
months. The median anti-TTG IgA concentration for
these 11 patients at time of initial biopsy rose from 2.4
X ULN (1.6–5 X ULN) to 3.6 X ULN (3.1–9.2 X ULN)
(p = 0.11) between biopsies (Fig. 2).
The anti-TTG IgA concentrations between the two
groups at time of initial biopsy was significantly lower in
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Fig. 1 Overview of the distribution of patients meeting inclusion criteria

the potential celiac disease group (p = 0.008) (Fig. 2).
However, there was no statistically significant difference
(p = 0.42) between anti-TTG IgA concentrations of the
celiac disease group and the potential celiac disease
group at time of subsequent diagnosis.
The median age at diagnosis of celiac disease in those
patients diagnosed on the initial biopsy was 10 (6–13)
years; the median age at diagnosis was 13 (9–15) years

in patients with potential celiac disease who progressed
to celiac disease (p = 0.03) (Table 1).
Patients with celiac disease confirmed on the initial biopsy had a median weight percentile of 49 (16–75) and
median height percentile of 58 (30–87). The median
weight percentile of patients with potential celiac disease
was 50 (25–70) at time of initial biopsy, and 55 (40–80)
at time of second biopsy when the diagnosis of celiac

Table 1 Demographic data and characteristics of study participants n (%)
Celiac disease
confirmed on
initial biopsy,
n = 316 (96)

Potential celiac disease, time Celiac disease vs
of initial biopsy,
potential celiac
n = 11 (4)
disease initial
biopsy p values

Potential celiac
disease, time of
second biopsy,
n = 11 (4)

Celiac disease vs
potential celiac
disease second
biopsy p values

13 (9–15)

p = 0.03*

Median age at diagnosis,
yr (IQR)

10 (6–13)

Female

220 (70)

8 (73)

p = 1.00

8 (73)

p = 1.00

Caucasian

307 (97)

11 (100)

p = 1.00

11 (100)

p = 1.00

Median HAZ (IQR)

(−)0.3 ((−)1.15–0.6)

(−)0.15 ((−)0.92–0.44)

p = 0.76

0.03 ((−)0.76–0.20) p = 0.71

Median WAZ (IQR)

(−)0.22 ((−)0.925–0.51) (−)0.04 ((−)0.78–0.47)

p = 0.93

0.39 ((−)0.62–0.85) p = 0.46

Median BMI percentile (IQR)

58 (27–84)

48 (41–75)

p = 0.89

59 (33–87)

p = 0.63

Median hemoglobin
concentration (IQR)

12.8 (11.9–13.6)

13.7 (12.7–14.9)

p = 0.10

13.8 (11.9–14.4)

p = 0.25

Median MCV (IQR)

82.6 (78.8–85.3)

87.4 (81.3–90.8)

p = 0.03*

83.3 (81.5–89.3)

p = 0.21

0 (0)

p = 0.22

0 (0)

p = 0.22

Family history of celiac disease 55 (17)
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Fig. 2 Anti-TTG IgA levels in patients with celiac disease on initial biopsy vs. potential celiac disease (initial biopsy without disease and second
biopsy with disease). Statistical significance determined using Mann Whitney test

disease was made. The median height percentile of
patients with potential celiac disease was 54 (34–82)
at time of initial biopsy, and 60 (22–67) at time of
diagnosis with second biopsy. There was no statistically significant difference in the weight and height
percentiles between the celiac disease and potential
celiac disease groups at time of either the initial or
second biopsy.
The median height-for-age Z-score (HAZ score) for
patients with celiac disease was − 0.3 (− 1.15–0.6),
compared to − 0.15 (− 0.92–0.44) for patients with potential celiac disease at the time of the first biopsy
(p = 0.76), and 0.03 (− 0.76–0.20) at the time of the
second biopsy (p = 0.71). The median weight-for-age
Z-score (WAZ score) for patients with celiac disease
was − 0.22 (− 0.925–0.51), compared to − 0.04 (−
0.78–0.47) for patients with potential celiac disease at
time of first biopsy (p = 0.93), and 0.39 (− 0.62–0.85)
at time of second biopsy (p = 0.46). There was again
no statistically significant difference in the HAZ and
WAZ scores between the celiac disease and potential
celiac disease groups at time of first or second biopsy
(Table 1).
Of the 316 patients diagnosed with celiac disease on
the initial biopsy, 146 had a hemoglobin concentration
obtained at time of diagnosis. Their median hemoglobin
concentration was 12.8 g/dl (11.9–13.6) and median
mean corpuscular volume (MCV) was 82.6 fL (78.8–
85.3) (Table 1). Of the 11 patients with potential celiac

disease who progressed to celiac disease, 7 had a
hemoglobin concentration available at time of first and
second biopsy. At time of first biopsy, their median
hemoglobin concentration was 13.7 g/dl (12.7–14.9), and
median MCV was 87.4 fL (81.3–90.8). At time of second
biopsy, the median hemoglobin concentration was 13.8
g/dl (11.9–14.4), and median MCV was 83.3 fL (81.5–
89.3). There was no statistically significant difference in
the hemoglobin concentrations or MCV between both
groups (Table 1).
Among the patient diagnosed with celiac disease on
the initial biopsy, 40 (12%) patients had been diagnosed
with type I diabetes mellitus (T1DM), 13 (4%) with
hypothyroidism, and 13 (4%) with trisomy 21. In those
patients with potential celiac disease which progressed
to celiac disease, 3 (27%) patients had T1DM, 2 (18%)
had hypothyroidism, and 2 (18%) had trisomy 21
(Fig. 3). There was no statistically significant difference
in prevalence of T1DM (p = 0.16), hypothyroidism (p =
0.09), or trisomy 21 (p = 0.09) between the groups.
However in the aggregate, 61 (19%) of patients with celiac disease on the initial biopsy had been diagnosed
with at least one of these three co-morbidities, versus 5
(45%) of the 11 patients in the potential celiac disease
group (p = 0.05). Additionally, five unique patients in
the celiac disease group had other inflammatory disorders of the digestive system: two (< 1%) had concomitant ulcerative colitis, and 3 (1%) had eosinophilic
esophagitis.
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Fig. 3 Disease co-morbidities in patients with celiac disease and potential celiac disease who progress to celiac disease on second biopsy.
Statistical significance determined using Fisher Exact test

Discussion
Prior studies of potential celiac disease [3, 4, 6] suggest
that intraepithelial lymphocytosis on initial biopsy may
be an early presentation of celiac disease. Auricchio
et al. [7] also suggested that both quantity and type of
intraepithelial lymphocytes may predict who subsequently develops celiac disease. In our study, 8 of our 11
patients (73%) with potential celiac disease had evidence
of non-specific inflammation with IEL, but their IEL was
described as mild on the biopsy, calling into question
the predictive value of this semi-quantitative
measurement.
A striking finding was the poor performance of using
a cutoff point of 10 X ULN to predict a diagnosis of celiac disease before (or in lieu of) performing a biopsy in
this North American population. Indeed, 67% of the patients with definite diagnosis of celiac disease on biopsy
had anti-TTG values less than this cutoff point, and 21%
had values less than 3 X ULN. Therefore, it may be
worthwhile to pursue duodenal biopsy even in patients
with anti-TTG values less than 3 X ULN.
Anti-EMA antibody has previously been reported as a
good predictor for the subsequent diagnosis of celiac
disease in patients whose initial biopsy is negative [8, 9].
In our study, 5 of the 11 patients with potential celiac
disease had an anti-EMA obtained. In these 5 patients,
anti-EMA was indeed correspondingly elevated at both
time of initial biopsy and second biopsy (see Supplementary Table 1), thereby supporting the potential use of
anti-EMA as a predictor for subsequent diagnosis of celiac disease when the initial biopsy is negative. We further demonstrated that the degree of circulating antiTTG IgA elevation also appears to correlate with the
histopathologic diagnosis of celiac disease as patients in
both our potential celiac disease and celiac disease

cohorts had a higher relative anti-TTG IgA concentration at the time when celiac disease was diagnosed.
However, there is insufficient overlap between groups to
make this value useful as a clinical tool.
The majority of patients within both cohorts were
non-Hispanic white, as supported in the literature [12,
14]. The female predominance resembles sex ratios of
other series of children with celiac disease [12, 15, 16].
However, there was a statistically significant difference
in age at time of diagnosis between the two cohorts, and
the potential celiac disease group had a higher proportion of co-morbidities which prompted screening. It is
possible that such lead time bias contributes to initially
negative biopsies, and these patients should especially be
considered to be at risk of subsequent diagnosis if their
initial biopsy is normal. The association of sex and presence of co-morbidities with subsequent diagnosis of celiac disease has been replicated in other studies on the
progression of celiac disease [17]. There was no difference in stature, weight, or hemoglobin concentrations
between the two cohorts, and in fact most patients in
both cohorts had normal growth and normal
hemoglobin concentrations, similar to recent series [18–
20]. We do note the previously described challenges in
interpretation of histopathology in celiac disease [21, 22]
as a limitation of our study, which relied on one pathologist’s review of biopsies. This known variability underlies inclusion of serology and history in a “synoptic”
assessment [23]. Additionally, we were unable to provide
Marsh scores or quantification of intraepithelial lymphocytes on biopsy, and instead relied on qualitative descriptors of the biopsy findings per pathology reports.
Lastly, because of the pragmatic nature of our study
anti-TTG IgA concentrations were obtained for clinical
purposes and were therefore performed using different
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assays, and potentially useful markers such as anti-EMA
and HLA genotyping were not uniformly ordered.
We also note that this study highlights a potential
shortcoming of the current celiac disease nomenclature.
The personalized natural history of celiac disease is now
recognized, but terms that embody the stages of progression are lacking. While potential celiac disease denotes
patients characterized by positive serological markers
and negative biopsies, there is no term which accurately
defines the subsets of these patients whose serology normalizes vs. those whose biopsies become positive. We
recognize that these classifications can only be made in
retrospect, but advocate for nosologic flexibility to describe an entity in the celiac spectrum that encompasses
progression as well as regression.

Conclusion
Based on our study findings and previous work [3, 4, 6–
9, 17], a subset of children with elevated celiac serologies
are at risk of subsequently being diagnosed with this disorder. The percentage we report, 4%, is likely to underestimate this risk, because we did not systematically
follow all patients with normal biopsies in this retrospective review. This study highlights the importance of
close monitoring of patients who present to providers
with concern for celiac disease and are found to have elevated anti-TTG IgA concentrations, even if their initial
biopsy was negative. Additionally, our study suggests
that even if the anti-TTG IgA levels are only modestly
elevated, it may still be worthwhile to obtain a small
bowel biopsy as some of these patients have evidence of
villous atrophy. These data suggest that changes in diagnostic protocols and disease categorization might be
warranted to optimize the management of children with
suspected celiac disease.
Abbreviations
SLCH: St. Louis Children’s Hospital; IQR: Interquartile range; ULN: Upper limit
of normal; TTG IgA: Tissue transglutaminase; EMA IgA: Anti-endomysial;
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